Evidence map›Paper›PMID 34859391›Full record

ArticleEndocrine2022

Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres.

Bushra Shahida, Kleoniki Tsoumani, Tereza Planck, Vijayachitra Modhukur, Pernilla Asp, Anna Sundlöv, Jan Tennvall, Peter Åsman, Ola Lindgren, Mikael Lantz

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. The C55A Single Nucleotide Polymorphism inDiagnostics (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bushra ShahidaDepartment of Clinical Sciences Malmö, Diabetes and Endocrinology, Lund University, Malmö, Sweden.
Kleoniki TsoumaniDepartment of Endocrinology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö and Lund, Sweden.
Tereza PlanckDepartment of Endocrinology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö and Lund, Sweden.
Vijayachitra ModhukurDepartment of Clinical Sciences Malmö, Diabetes and Endocrinology, Lund University, Malmö, Sweden.
Pernilla AspDepartment of Oncology, Skåne University Hospital, Lund, Sweden.
Anna SundlövDepartment of Oncology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Jan TennvallDepartment of Oncology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Peter ÅsmanDepartment of Clinical Sciences Malmö, Ophthalmology, Skåne University Hospital, Department of Ophthalmology, Lund University, Malmö, Sweden.
Ola LindgrenDepartment of Endocrinology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö and Lund, Sweden.
Mikael LantzDepartment of Endocrinology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Malmö and Lund, Sweden. Mikael.Lantz@med.lu.se.ORCID http://orcid.org/0000-0003-3445-9090
Lund University · SESkåne University Hospital · SE

Funding

Direktör Albert Påhlssons Stiftelse 2021Medicinska Fakulteten, Lunds Universitet 2021Region Skåne 2021
6 · The paper itself

Abstract

introductionTreatment of Graves´ disease (GD) with radioiodine increases the risk of developing Graves´ ophthalmopathy (GO), and the link between thyroid and orbital tissue may be the presence of TSH-receptors. Radioiodine increases the titers of TRAb and the aim was to investigate the relationship between GO and TRAb titers after treatment with radioiodine and to define the impact of risk genes.

methodsGD patients without ophthalmopathy or previous treatment with radioiodine were prospectively included at treatment with radioiodine for hyperthyroidism. A follow-up was performed 1 year later for the registration of GO development. The study was performed at a University Hospital Clinic; a referral center of all patients treated with radioiodine in the south of Sweden. The main outcome measures were the development of TRAb, anti-TPO, and anti-TG after 3 months and GO after 12 months and relationship to the genetic background (HLA, CTLA-4, and CYR61).

resultsThree months of radioiodine TRAb titers increased in two thirds of patients (p < 0.0005) but not in the other third. Anti-TPO titers were associated with TRAb (R = 0.362, p < 0.0001) but not anti-TG. At follow-up 1 year later (n = 204) 32 patients developed GO with a proportion of 70% in the group increasing in TRAb titers and 30% in the group with unchanged or lower TRAb titers (p-value < 0.0005). Patients with GO had higher titers of TRAb than patients without GO. CTLA-4 (rs231775 SNP) was significantly (p < 0.005) associated with TRAb titers above the median three months after radioiodine.

conclusionsThe increase in TRAb titers after treatment with radioiodine is associated with GO and a genetic variation in CTLA-4 is associated with higher titers of TRAb.

Indexed as

Graves DiseaseGraves OphthalmopathyAutoantibodiesCTLA-4 AntigenHumansIodine RadioisotopesReceptors, ThyrotropinAutoantibodiesCTLA-4 AntigenCTLA4 protein, humanIodine RadioisotopesReceptors, ThyrotropinAnti-TGAnti-TPOCTLA-4Graves´ diseaseRadioiodineTRAb

Identifiers

PMID34859391
PMCPMC8888513
OpenAlexW3200908449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.